Promise, Innovation, Potency, and Efficacy: The PIPE Dream of Sodium-Glucose Co-Transporter 2 Inhibitors

Arguably, no class of medications, specifically for patients with type 2 diabetes mellitus, has garnered as much excitement as the sodium-glucose co-transporter 2 (SGLT2) inhibitors. Type 2 diabetes mellitus is a highly prevalent and growing global problem, and patients with type 2 diabetes mellitus are at high risk for cardiovascular and renal end-organ damage, complications, and mortality. Until recently, there was no proven therapy that reduced the risk of cardiovascular adverse events or death in these patients.